CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.69
-0.02 (-3.25%)
▼
5d:
+0.71%
30d:
-17.37%
90d:
+9.55%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTOR trades at premium valuation expecting 33.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: CTOR trades at premium valuation expecting 33.2% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.69, which is considered oversold relative to its 30-day fair value range of $0.69 to $0.85. From a valuation perspective, the stock is trading at a premium (Forward PE: 7.1) compared to its historical average (3.0). At these levels, the market is pricing in 33.2% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.85. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: CTOR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.00 (+465.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.85. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: CTOR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.00 (+465.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.69 -
$0.85
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 465.0% below Wall St target ($4.00)
- BEARISH: Market expects 33.2% growth - appears too optimistic based on history
Trading Range Analysis
30-Day Trading Range
$0.69 -
$0.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$0.85
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.08
Wall Street Target
$4.00
(+465.0%)
Valuation Premium vs History
+33.2% premium
PE vs Historical
7.1 vs 3.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+33.2%
(market-implied from PE analysis)
1-Year Target
$0.94
(+33%)
2-Year Target
$1.26
(+77%)
3-Year Target
$1.67
(+136%)
3-Yr Target (if PE normalizes)
(PE: 7→3)
PE COMPRESSION
$0.71
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 23, 2026 4:16 PM ET
Data refreshes hourly during market hours. Next update: 5:16 PM
Data refreshes hourly during market hours. Next update: 5:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |